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INTRODUCTION
Patients with type 2 diabetes mellitus are at in-
creased risk for cardiovascular disease (1, 2), which
is attributed in part to lipid abnormalities commonly
associated with type 2 diabetes and metabolic syn-
drome (3). Reduction in the low-density lipoprotein
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cholesterol (LDL-c) levels constitutes the basis for
the prevention of cardiovascular disease (4). Aggres-
sive therapy to lower the LDL-c levels was associ-
ated with a subsequent reduction in the rates of car-
diovascular events in recent comparative trials of dif-
ferent statins or the same statin at different doses (5-
8). However, when the statin dose is increased to
the maximum approved level, there is only limited
additional lowering of LDL-c with an increase in
the incidence of side effects (9).
The recently introduced ezetimibe (10, 11), which
selectively inhibits dietary and biliary cholesterol ab-
sorption by binding to the Niemann-Pick C1-like 1
(NPC1L1) protein (12-15) at the brush-border mem-
brane of enterocytes, appears to be an interesting
add-on therapy to low-dose statins to obtain signifi-
cant improvement in the different lipid parameters
without increasing the statin dose, and thus, to pre-
vent dose-related side effects (16, 17). In this study,
we evaluated the changes in the lipid profile, glucose
metabolism, and marker levels that reflect on the
effect of ezetimibe treatment on the absorption and
synthesis of cholesterol in hypercholesterolemic pa-
tients with or without diabetes. We also investigated
the clinical characteristics of patients who show a
better response to ezetimibe (ezetimibe responders)
and who thus are more likely to benefit from the
treatment than other patients.
METHODS
The outpatients of National Center for Global
Health and Medicine with LDL-c levels higher than
the levels recommended in the Japan Atheroscle-
rosis Society (JAS) guidelines for prevention of athe-
rosclerotic cardiovascular disease (18) were the sub-
jects of this study. The patients in the monotherapy
group were administered only ezetimibe (10 mg/
day). The patients in the combination therapy group
were administered ezetimibe as an add-on therapy
to common lipid-regulating agents including low-
dose statins (simvastatin, pravastatin, atorvastatin,
pitavastatin, and rosuvastatin) and fenofibrates.
The patients were allowed to continue with their
other medications and daily activities during the
study. A physical examination of all the patients in-
cluding measurements of height, body weight, body
mass index (BMI) (calculated as the ratio of weight
to the square of height), and blood pressure was
conducted at the start and at 4 weeks and 12 weeks
after ezetimibe administration ; in addition, blood
tests were performed for liver and kidney function,
serum lipids, fasting plasma glucose (FPG), and
hemoglobin A1c (HbA1c) (19) by routine laboratory
methods. C-reactive protein (CRP), remnant-like
lipoprotein cholesterol (RLP-c), insulin, glycated al-
bumin (GA), markers for cholesterol absorption
(cholestanol, campesterol, and sitosterol), and 1
marker for cholesterol synthesis (lathosterol) were
also assessed. RLP-c was analyzed by the immu-
noabsorption method using Hitachi automatic ana-
lyzer 7170 (Hitachi Ltd., Tokyo), and cholesterol
synthesis and absorption markers were analyzed in
a GC-2010 capillary gas chromatograph (Shimadzu
Co., Kyoto) by gas-liquid chromatography. Blood
was sampled in fasting conditions for all measure-
ments. Ezetimibe safety and tolerance were evalu-
ated throughout the study by analysis of the patient
reports and results of measurements of liver and
kidney function.
Statistical analysis was performed with Student’s
paired t -test or the Wilcoxon signed rank test using
STATA version 11 (StataCorp LP, College Station,
TX). LDL-c levels were calculated by the Friede-
wald equation, and triglyceride values were loga-
rithmically transformed to obtain a normal distribu-
tion before statistical analysis. The rates of changes
in LDL-c and those of each lipid were calculated by
dividing the difference between the latter and for-
mer value by the former value. A p value of 0.05
were considered statistically significant.
The study was conducted according to the prin-
ciples of the Declaration of Helsinki, and the patients
provided their written informed consent after the
purpose and potential risks of the study were ex-
plained to them.
RESULTS
Table 1 lists the basic characteristics of the pa-
tients of the monotherapy and combination therapy
groups. In the monotherapy group, 20 of 24 patients
and in the combination therapy group, 15 of 26 pa-
tients were diabetic. These diabetic patients were
treated with diet and exercise, and some were
treated with antidiabetic agents. Table 2 shows
changes in BMI, BP, liver and kidney function, and
CRP levels. The BMI and blood pressure of the pa-
tients did not change significantly during the study.
During the ezetimibe administration, no serious ad-
verse events related to liver and kidney dysfunction
were noted in any patient. There were no significant
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changes in the CRP levels at 12 weeks of ezetimibe
administration in all patients.
Lipid profile
In all patients (Table 3), LDL-c levels were sig-
nificantly reduced from 155.23.7(meanS.E.) mg/
dL at baseline to 120.53.9 mg/dL at 4 weeks of
treatment and to 123.53.6 mg/dL at 12 weeks of
treatment. In all patients, total cholesterol (TC) lev-
els were also reduced significantly from 241.64.6
mg/dL at baseline to 205.54.4 mg/dL at 4 weeks
of treatment and to 210.84.6 mg/dL at 12 weeks
of treatment. A significant reduction of LDL-c and
TC levels was noted at 4 and 12 weeks of treatment
in diabetic patients in both the monotherapy and
combination therapy groups and non-diabetic pa-
tients in only the combination therapy group (Table
4). No significant changes were noted in the levels
of high-density lipoprotein cholesterol (HDL-c) lev-
els and RLP-c levels overall, but a significant reduc-
tion at 12 weeks of treatment as compared to the
initial levels was noted in HDL-c and RLP-c levels
in the diabetic patients of the monotherapy. No sig-
nificant changes were observed in the triglyceride
levels in all patients throughout the study period.
Glucose metabolism
At 12 weeks of ezetimibe administration in all pa-
tients, no significant changes were noted in the
FPG, HbA1c, GA, level of insulin resiatance and β -
cell function as estimated using the homeostatic
model assessment (HOMA) (20) of insulin resis-
tance (IR) and HOMA of β -cell function (β) (Table
5).
Table 1 Patient characteristics at baseline
The values represent meanSD ; these values were obtained
at the baseline, i.e., before ezetimibe monotherapy and before
combination therapy. DM, diabetes mellitus ; SBP, systolic blood
pressure ; DBP, diastolic blood pressure
Monotherapy
All (N=24) DM (N=20) non-DM (N=4)
Age (yrs) 59.711.0 61.49.5 51.015.7
Male/Female 10/14 10/10 0/4
Bodyweight (kg) 66.814.8 68.015.1 60.713.3
BMI (kg/m2) 25.84.9 25.74.8 26.36.1
SBP (mmHg) 124.417.0 126.917.0 112.012.1
DBP (mmHg) 71.69.3 72.110.1 69.02.0
Combination therapy
All (N=26) DM (N=15) non-DM (N=11)
Age (yrs) 62.411.6 66.711.3 63.014.3
Male/Female 10/16 6/9 4/7
Bodyweight (kg) 62.511.6 61.78.3 63.615.8
BMI (kg/m2) 24.93.7 25.04.8 24.84.5
SBP (mmHg) 127.111.9 124.912.2 130.411.3
DBP (mmHg) 70.99.3 68.910.6 73.86.4
Table 2 Changes in the measurements of the physical and
laboratory test parameters for all patients
The values represent meanSE.
at baseline 4 weeks 12 weeks
BMI (kg/m2) 25.350.61 25.370.61 25.370.63
SBP (mmHg) 125.82.1 123.92.0 126.92.2
DBP (mmHg) 71.21.3 67.01.4 70.41.3
AST (U/L) 23.81.5 24.51.5 23.88.9
ALT (U/L) 23.62.2 25.62.4 24.81.9
γ -GTP (U/L) 44.67.6 41.36.7 46.97.9
LDH (U/L) 206.37.3 208.77.3 217.58.7
ALP (U/L) 216.410.3 221.110.4 222.410.8
ChE (U/L) 350.87.9 343.39.6 355.18.0
CPK (U/L) 108.67.3 111.67.5 111.18.7
BUN (mg/dl) 14.00.7 14.30.7 14.50.6
Cr (mg/dl) 0.720.03 0.730.04 0.730.04
UA (mg/dl) 4.900.15 4.870.17 4.900.16
CRP (mg/dl) 0.170.05 0.120.02
Table 3 Changes in the lipid profile and in the levels of markers of cholesterol absorption/synthesis in all patients
The values represent meanSE ; these values were obtained at the baseline and at 4 and 12 weeks. The values under “Change (%)
at 4 w” and “Change (%) at 12 w” are presented as percent changes from the baseline to 4 weeks and from the baseline to 12 weeks
(meanSD), respectively. Endpoint measurement for every variable was not obtained in the case of all patients. Statistical analysis
was performed using the paired t - test (*p0.05).
at baseline 4 weeks change (%) at 4 w 12 weeks Change (%) at 12 w
TC (mg/dl) 241.64.6 205.54.4* -14.410.8 210.84.6* -12.511.5
LDL-c (mg/dl) 155.23.7 120.53.9* -21.715.3 123.53.6* -19.415.7
HDL-c (mg/dl) 57.01.7 57.01.8 0.611.3 55.71.9 -1.911.7
Triglyceride (mg/dl) 146.98.2 140.09.1 -3.328.1 153.710.6 6.640.1
RLP-c (mg/dl) 6.510.43 5.940.52 -5.443.7
Cholestanol (μg/ml) 3.140.12 2.820.11* -6.626.6
Sitosterol (μg/ml) 3.640.30 2.040.13* -38.519.7
Campesterol (μg/ml) 5.580.56 2.630.19* -45.620.9
Lathosterol (μg/ml) 3.000.28 3.950.33* 51.179.3
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Table 4 Changes in the lipid profile and in the levels of cholesterol absorption/synthesis markers of the monotherapy group and
combination group
The values represent meanSE ; these values were obtained at the baseline and at 4 and 12 weeks. Endpoint measurement for
every variable was not obtained in the case of all patients. Statistical analysis was performed using the paired t - test (*p0.05).
Monotherapy
DM non-DM
Baseline 4 weeks 12 weeks Baseline 4 weeks 12 weeks
TC (mg/dl) 236.36.8 199.96.3* 201.66.0* 250.316.5 224.317.8 225.814.4
LDL-c (mg/dl) 152.95.1 119.34.9* 123.14.7* 157.721.1 133.516.9 134.217.6
HDL-c (mg/dl) 57.72.4 55.32.3 54.92.7* 61.07.0 61.89.0 62.28.2
Triglyceride (mg/dl) 133.512.9 122.915.1 122.59.8 157.833.1 145.326.4 146.525.2
RLP-c (mg/dl) 6.380.76 4.980.46* 6.301.01 5.781.20
Cholestanol (μg/ml) 3.060.19 2.730.18 2.480.20 2.850.39
Sitosterol (μg/ml) 3.860.39 2.010.14* 2.250.38 1.630.34*
Campesterol (μg/ml) 5.830.74 2.560.23* 3.600.60 2.230.17*
Lathosterol (μg/ml) 3.260.38 4.410.51* 3.230.54 4.280.45*
Combination therapy
DM non-DM
Baseline 4 weeks 12 weeks Baseline 4 weeks 12 weeks
TC (mg/dl) 227.97.1 191.76.1* 208.98.2* 266.69.8 227.910.2* 225.212.8*
LDL-c (mg/dl) 144.34.9 108.26.3 117.36.9 171.97.9 133.810.3 127.79.2
HDL-c (mg/dl) 51.72.6 54.12.6 52.92.7 61.34.7 61.94.9 60.65.2
Triglyceride (mg/dl) 146.114.0 145.216.9 176.426.4 167.218.3 161.218.2 184.321.4
RLP-c (mg/dl) 6.150.85 6.571.49 7.310.72 6.900.92*
Cholestanol (μg/ml) 3.300.28 3.080.22 3.320.17 2.620.20*
Sitosterol (μg/ml) 4.130.84 2.380.33* 3.180.35 1.830.26*
Campesterol (μg/ml) 6.461.52 3.080.50* 4.760.73 2.340.33*
Lathosterol (μg/ml) 2.650.69 3.870.82* 2.890.52 3.120.50
Table 5 Levels of glucose metabolism in patients of the monotherapy group and combination group
The values represent median (interquartile range). Statistical analysis was performed using the Wilcoxon-signed rank test. The value
for HbA1c (%) is estimated as an NGSP equivalent value (%) calculated by the formula HbA1c (%)=HbA1c (JDS)(%)+0.4%, consider-
ing the relational expression of HbA1c (JDS)(%) measured by the previous Japanese standard substance and measurement methods
and HbA1c (NGSP).
Monotherapy
DM non-DM
Baseline After 12 weeks p value Baseline After 12 weeks p value
FPG (mg/dL) 136.5 (122.5-153.0) 138.0 (123.0-151.0) 0.6435 96.0 (89.9-100.0) 95.5 (91.0-98.0) 0.8527
HbA1c (%) 6.7 (6.7 -7.35) 7.1 (6.6 -7.5) 0.6002 5.65 (5.45-5.95) 5.65 (5.50-5.85) 0.8539
GA (%) 19.4 (17.6-20.5) 18.9 (17.6-19.5) 0.2431 14.9 (12.2-17.6) 14.4 (14.3-16.8) 0.4652
HOMA-IR 1.99 (1.34-2.78) 2.09 (1.52-4.11) 0.5732 1.71 (1.02-2.76) 1.75 (1.13-3.62) 0.4652
HOMA-β 33.1 (19.1-42.3) 32.0 (25.1-50.4) 0.6874 65.8 (46.1-176.9) 77.52 (53.6-212.0) 0.1441
Combination therapy
DM non-DM
Baseline After 12 weeks p value Baseline After 12 weeks p value
FPG (mg/dL) 132.0 (115.0-156.0) 136.0 (108.0-176.0) 0.8505 98.0 (92.0-101.0) 100.5 (90.0-107.0) 0.2371
HbA1c (%) 7.3 (6.7 -7.6) 7.5 (6.7 -7.9) 0.1631 5.8 (5.6 -6.1) 5.9 (5.7 -6.1) 0.1301
GA (%) 18.3 (17.2-22.4) 20.3 (16.3-24.0) 0.2557 13.9 (12.9-15.6) 14.0 (12.7-14.8) 0.2017
HOMA-IR 1.98 (1.32-2.64) 2.45 (1.05-2.96) 0.124 1.60 (0.87-2.59) 2.49 (1.40-3.67) 0.1394
HOMA-β 30.0 (18.7-42.8) 28.7 (15.0-58.0) 0.3305 70.0 (33.1-135.6) 93.2 (61.9-129.1) 0.2411
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Changes in the cholesterol absorption and synthesis
marker levels
A significant reduction of 6.626.6 (mean
S.D.) % in the levels of cholestanol, a marker for
cholesterol absorption, was noted at 12 weeks of
ezetimibe administration in all patients (Table 3) ;
in addition, a significant reduction was also noted
in the non diabetic patients in the combination ther-
apy group (Table 4). A significant reduction of
38.519.7% and 45.620.9% was noted in the levels
of other cholesterol markers, sitosterol and camp-
esterol, respectively in all patients (Table 3). A sig-
nificant elevation of 51.179.3% as compared to the
initial levels was noted in the levels of lathosterol,
a marker for cholesterol synthesis, at 12 weeks of
treatment in all patients except the nondiabetic pa-
tients of the combination therapy group (Table 4).
Scattergram illustrating a relation between the rates
of changes in the levels of LDL cholesterol and cho-
lesterol absorption/synthesis markers (Fig. 1).
There was a positive relation between the rates of
changes in the levels of each marker and LDL-c.
Therefore, the LDL-c values decreased with the
increase in the changes of absolute values of each
marker induced by ezetimibe administration ; these
results reflect the pharmacokinetics of ezetimibe.
Ezetimibe responders
We attempted to determine certain characteris-
tics of the ezetimibe responders. We considered a
patient to be an ezetimibe responder if 1) the LDL-
c level in that patient reduced by 20% as com-
pared to the initial value and/or 2) the LDL-c level
in that patient reduced to120 mg/dL by eztimibe
administration. Among all patients, the first condi-
tion was noted in 21 patients and the second in 25
patients ; both conditions were noted in 18 patients.
However, no correlation was noted by multivariate
regression analysis between ezetimibe efficacy and
patient characteristics such as gender, age, and
BMI. In addition, neither a diabetic condition nor
the administration method of ezetimibe as a mono-
therapy or in combination with other drugs were
found to be related to ezetimibe efficacy, and the
initial absolute values of cholestanol, sitosterol,
campesterol, and lathosterol were also not related
to ezetimibe efficacy.
Fig. 1 The scattergram
Correlation between the rates of changes in LDL-c and the rates of changes in each of the cholesterol absorption/synthesis markers.
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DISCUSSION
Our study results were compatible with those of
a short-term randomized controlled trial (RCT) (21)
and other reports (17, 22-25) which showed that
ezetimibe was clinically effective in reducing LDL-c
when administered as monotherapy or in combina-
tion with a statin. The results of our study using ab-
sorption/synthesis markers confirmed that ezetimibe
selectively inhibits the absorption of cholesterol and
is associated with a rebound increase in cholesterol
synthesis (26, 27). Previous study reports indicate
that ezetimibe administration elevates HDL-c levels
and reduces triglyceride levels (4) ; however, these
changes were not observed in our study.
Statins have a potent cholesterol-lowering effect,
but certain types of statins should be used cautiously
because they can impair glycemic control (28, 29).
Atorvastatin has been reported in some cases to dis-
rupt glycemic control in patients with type 2 diabetes
(30. 31). The mechanism by which atorvastatin dis-
rupt glycemic control remains unknown ; however,
atorvastatin was shown to inhibit adipocyte matura-
tion and glucose transporter 4 (Glut4) expression by
blocking isoprenoid biosynthesis, thus impairing glu-
cose tolerance (32). In addition, atorvastatin was re-
ported to impair insulin secretion (33) ; this suppres-
sive effect occurs probably because atorvastatin and
similar lipophilic statins cause β -cell cytotoxicity and
sterol regulatory-element binding protein (SREBP)
activation (30). Hiramitsu et al . (34) reported that
ezetimibe treatment reduces the fasting serum in-
sulin level and HbA1c in the Japanese population. In
our study, no statistically significant changes were
noted in the levels of the parameters for glucose me-
tabolism in both diabetic and nondiabetic patients
when ezetimibe was administered as monotherapy
or in combination with a statin. Because the number
of patients in this study was small, studies with a
larger patient group need to be performed to con-
firm this result.
From a medical and a socio-economical perspec-
tive, it is important to identify “responders” for a
certain drug among a patient population. Theoreti-
cally, ezetimebe should work more effectively in pa-
tients who exhibit high levels of absorption marker,
such as cholestanol, sitosterol, and campesterol, or
low levels of cholesterol synthesis markers, such as
lathosterol ; this hypothesis is based on the pharma-
cokinetics and effects of ezetimibe and the fact that
not all patients respond to statins ; this lack of re-
sponse is assumed to be because of high rate of
absorption and low rate of synthesis of cholesterol
observed in some patients (35). Increased choles-
terol synthesis has been observed in obese subjects
(36), patients with metabolic syndrome (3, 37, 38)
and type 2 diabetes patients (39, 40) ; however, an
earlier study suggests that cholesterol absorption is
increased in obese subjects (41). It was quite inter-
esting to investigate whether patients exhibiting high
levels of absorption markers benefited from ezetimibe
administration and whether the existence of obesity
or diabetes affected ezetimibe efficacy. Diabetic pa-
tients have been reported to have higher NPC1L1
mRNA levels than control subjects (42), and thus,
we expected that ezetimibe will be more beneficial
for diabetic patients. However, the absolute values of
cholesterol absorption and synthesis marker were
not found to be related with the existence of diabetes
or obesity in the likely ezetimibe responders. For a
definite answer to this issue, an investigation needs
to be conducted on a larger number of patients.
Elevated CRP levels indicate a low-grade inflam-
mation, which is associated with endothelial dysfunc-
tion. Previous studies indicate that at all doses, statins
when coadministered with ezetimibe induce signifi-
cantly lower high-sensitivity CRP levels than when
administered as monotherapy (43-45) ; this sug-
gests an additional antiinflammatory/anti-atheroscle-
rotic action of the combination therapy. In our study,
there were no significant changes noted in the CRP
levels in all patients ; however, a significant reduc-
tion in the serum levels of high-sensitivity CRP has
been reported in the Japanese population (34), the
clinical implications of which remain to be studied.
Our study had the following limitations. Ezetimibe
was administered for a short period, and the num-
ber of the patients studied was small. We also ex-
cluded a patient who dropped out during the treat-
ment. Although we had instructed the patients to
continue with their normal activities during the
study period and conducted the study throughout
the year to eliminate seasonal influences, there may
be some variations in factors such as diet and ex-
ercise, thus affecting lipid profile and glucose me-
tabolism. Finally, the population of only a single eth-
nicity, i.e., the Japanese, was studied ; the results of
a similar study in other ethnic populations may vary.
CONCLUSION
In conclusion, ezetimibe can be considered to be
an efficacious and well-tolerated drug for dyslipidemia
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on the basis of our study results. Because we were
unable to identify the specific characteristics of
ezetimibe responders among our subjects, we pro-
pose that ezetimibe can be used in any population
to lower the LDL-c levels.
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